search
Back to results

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

Primary Purpose

Diabetic Foot Ulcer

Status
Unknown status
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
vancomycin-tobramycin-itraconazole
Sponsored by
University of Mississippi Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 1 or Type 2 diabetes mellitus
  • An open DFU / wound of any size (including those requiring debridement in operation room or clinic setting) with or without a secondary fungal infection
  • ≥ 18 years of age
  • Treatment naïve or treatment failure with oral antibiotics to current wound infection

Exclusion Criteria:

  • Patients who present with untreated or on active-treatment for osteomyelitis, exposed bone, or have a life-threatening need of immediate surgery.
  • Patients who are allergic to any components of the investigated product.
  • Patients who have ≥ 15 shoe size
  • Patients who have received IV antibiotics within the past 30 days
  • Patients with HgbA1C > 14
  • Patients on active cancer treatment
  • Patients needing re-vascularization of the affected area but did not receive treatment.
  • Patients diagnosed with HIV/AIDs
  • Patients unable or unwilling to obtain and wear off-loading footwear

Sites / Locations

  • University of Mississippi Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment of Diabetic Foot Ulcer

Arm Description

Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.

Outcomes

Primary Outcome Measures

Healing Rate
We will be looking at measurements of the wound at the start of the study and at each study visit until the wound is healed, or the study has ended. The wounds are measured with a ruler by the provider seeing the patient at the time of the visit in centimeters. The wounds are also photographed with a ruler in the photograph for size.

Secondary Outcome Measures

Wound Closure
Assessing how many patients wounds closed during the study and the time in weeks it took for the patient to close their wound.

Full Information

First Posted
September 30, 2021
Last Updated
September 30, 2021
Sponsor
University of Mississippi Medical Center
Collaborators
Keystone Pharmacy
search

1. Study Identification

Unique Protocol Identification Number
NCT05076955
Brief Title
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy
Official Title
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 31, 2021 (Actual)
Primary Completion Date
August 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Mississippi Medical Center
Collaborators
Keystone Pharmacy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Diabetic foot ulcers (DFUs) are a frequent clinical problem observed in diabetic patients. Properly managed, most can be cured, but many patients needlessly undergo amputations because of improper diagnostic and therapeutic approaches. The purpose of this study is to evaluate the effectiveness of a compounded, anti-infective irrigation therapy to increase the healing rates of diabetic foot ulcers and thereby provide a new therapeutic option for health care providers treating high-risk patients with DFUs regardless if secondary fungal infections are present. Participants diagnosed with diabetes type 1 or 2 and with a documented open diabetic foot ulcer/wound with or without a secondary fungal infection will be included in this prospective, active intervention pilot study. Healing rates will be evaluated every two weeks following the initiation of study therapy up to three months. Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. Participants will be asked to return to clinic every two - four weeks for assessment of the ulcer and compliance with treatment. A sample size of approximately 100 patients is estimated to have 90% power to detect 15% improvement in ulcer healing rates to 45% and 35% compared to historical benchmarks of approximately 30% for ulcers of <6 months duration and 20% for ulcers ≥6 months duration and/or prior treatment failure, respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
All participants receive the same intervention.
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment of Diabetic Foot Ulcer
Arm Type
Experimental
Arm Description
Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
Intervention Type
Drug
Intervention Name(s)
vancomycin-tobramycin-itraconazole
Intervention Description
Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
Primary Outcome Measure Information:
Title
Healing Rate
Description
We will be looking at measurements of the wound at the start of the study and at each study visit until the wound is healed, or the study has ended. The wounds are measured with a ruler by the provider seeing the patient at the time of the visit in centimeters. The wounds are also photographed with a ruler in the photograph for size.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Wound Closure
Description
Assessing how many patients wounds closed during the study and the time in weeks it took for the patient to close their wound.
Time Frame
Until the wound is closed up to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 1 or Type 2 diabetes mellitus An open DFU / wound of any size (including those requiring debridement in operation room or clinic setting) with or without a secondary fungal infection ≥ 18 years of age Treatment naïve or treatment failure with oral antibiotics to current wound infection Exclusion Criteria: Patients who present with untreated or on active-treatment for osteomyelitis, exposed bone, or have a life-threatening need of immediate surgery. Patients who are allergic to any components of the investigated product. Patients who have ≥ 15 shoe size Patients who have received IV antibiotics within the past 30 days Patients with HgbA1C > 14 Patients on active cancer treatment Patients needing re-vascularization of the affected area but did not receive treatment. Patients diagnosed with HIV/AIDs Patients unable or unwilling to obtain and wear off-loading footwear
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laura R Vick, MD
Phone
601-278-6213
Email
lvick@umc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Kirby Orme, MD
Phone
601-984-5080
Email
korme@umc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura R Vick, MD
Organizational Affiliation
University of Mississippi Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Mississippi Medical Center
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura R Vick, MD
Phone
601-278-6213
Email
lvick@umc.edu
First Name & Middle Initial & Last Name & Degree
Kirby Orme, MD
Phone
601-984-5080
Email
korme@umc.edu
First Name & Middle Initial & Last Name & Degree
Gloria Jaques, NP
First Name & Middle Initial & Last Name & Degree
Kirby Orme, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
We plan to share deidentified data that is collected in the study in full. All IPD that will result in publication.
IPD Sharing Time Frame
At the end of the study for a period of 6 months or until publication.
Citations:
PubMed Identifier
22619242
Citation
Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346.
Results Reference
background
PubMed Identifier
29377202
Citation
Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018 Jan;1411(1):153-165. doi: 10.1111/nyas.13569.
Results Reference
background

Learn more about this trial

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

We'll reach out to this number within 24 hrs